Latest Marten Transport (MRTN) Headlines Marten
Post# of 24
Marten Transport Declares Quarterly Dividend
GlobeNewswire - Fri Mar 07, 3:01PM CST
Marten Transport, Ltd. (Nasdaq:MRTN) announced today that its Board of Directors has declared a regular quarterly cash dividend of two and one half cents ($0.025) per share of common stock. The dividend will be payable on April 4, 2014 to stockholders of record at the close of business on March 21, 2014.
Marten Transport, Ltd. to Participate in the Stifel Transportation and Logistics Conference and the BB&T Capital Markets Transportation Services Conference
GlobeNewswire - Wed Feb 05, 3:15PM CST
Marten Transport, Ltd. (Nasdaq:MRTN) announced today that the Company is scheduled to present in the Stifel Transportation and Logistics Conference at the Eau Palm Beach Resort and Spa in Manalapan, Florida on Wednesday, February 12, 2014 at 11:30 A.M. Eastern Time, and in the BB&T Capital Markets Transportation Services Conference at the Biltmore Hotel in Coral Gables, Florida on Thursday, February 13, 2014 at 8:40 A.M. Eastern Time.
Shares of MRTN Up 10.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jan 29, 11:20AM CST
SmarTrend identified an Uptrend for Marten Transport (NASDAQ:MRTN) on October 28th, 2013 at $17.66. In approximately 3 months, Marten Transport has returned 10.93% as of today's recent price of $19.59.
Marten Transport Shares Up 17.8% Since SmarTrend's Buy Recommendation (MRTN)
Comtex SmarTrend(R) - Wed Jan 22, 10:04AM CST
SmarTrend identified an Uptrend for Marten Transport (NASDAQ:MRTN) on October 28th, 2013 at $17.66. In approximately 3 months, Marten Transport has returned 17.78% as of today's recent price of $20.80.
Microneedle Drug Delivery Systems to 2018
M2 - Wed Jan 22, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/dk8d4x/microneedle_drug) has announced the addition of the "Microneedle Drug Delivery Systems to 2018" report to their offering. Microneedle technology is attaining commercial viability at a time when drug developers are faced with new challenges as they assess ways to administer new classes of compounds with significant therapeutic potential. The widespread availability of rapid throughput screening is accelerating the discovery of new drugs, a significant number of which are large-molecule therapeutic compounds that cannot tolerate passage through the digestive system, requiring pharmaceutical companies to forego oral formulations and select alternate routes of administration. Highlights - Provides assessments of microneedles drug delivery devices, patches, syringes and systems - Analyzes and evaluates microneedle technology and assesses the medical market potential for existing and probable future products - Provides detailed descriptions of microneedle system business opportunities, market demographics, and business strategies - Provides market data and forecasts to 2018 - Profiles microneedle drug delivery product and technology participants, their activities, business strategies, and corporate alliances and affiliations Key Topics Covered Executive Summary Microneedle Medical Market Overview - Drug Delivery & Self-Administration - Chronic Conditions & Dosing Frequency - Patient Safety and Compliance - Microneedle Market Drivers - The Trend to Minimally Invasive Medicine - Shifting Patient Demographics - Managed Care Initiatives - Government Technology Transfer Programs Microneedle Design & Technology - Microneedle Form Factors - Solid Microneedles - Hollow Microneedles - Coated Microneedles - Dissolvable Microneedles - Microneedle Arrays & Array Geometries - Microneedle Manufacturing - Material Selection Issues - Fabrication Techniques - Emerging Fabrication Methods Medical Microneedles - Assessments & Commercialization Prospects Solid Microneedle Arrays Hollow Microneedle Arrays Silicon Microneedles Phase Transition Microneedle Patch Dissolving Microneedle Chip Syringe Mounted Microneedles Programmable Microneedle Patch Near-Terms Markets - Sector Assessments and Forecasts - Dermatology/Cosmetic Surgery - Genetic/DNA/Nucleotide Therapeutics - Osteoporosis - Reproductive Medicine - Vaccines Company Profiles For more information visit http://www.researchandmarkets.com/research/dk...eedle_drug About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Marten Transport Announces Fourth Quarter and Year End Results
GlobeNewswire - Tue Jan 21, 3:01PM CST
Marten Transport, Ltd. (Nasdaq:MRTN) today reported the highest net income for any year in its history. For the year ended December 31, 2013, net income improved 10.6% to a record $30.1 million, or 90 cents per diluted share, from $27.3 million, or 82 cents per diluted share, in 2012. For the fourth quarter of 2013, net income decreased to $7.3 million, or 22 cents per diluted share, from $7.7 million, or 23 cents per diluted share, in the fourth quarter of 2012.
CSX Corp Earnings Decline on Coal Woes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 8:30AM CST
CSX Corporation reported fourth quarter 2013 earnings of 42 cents per share
Marten Transport, Ltd. to Participate in the Raymond James Global Airline/Transportation Conference and in the Stephens Fall Investment Conference
GlobeNewswire - Tue Oct 29, 3:48PM CDT
Marten Transport, Ltd. (Nasdaq:MRTN) announced today that the Company is scheduled to present in the Raymond James Global Airline/Transportation Conference at the New York Marriott East Side in New York, New York on Wednesday, November 6, 2013 at 11:00 A.M. Eastern Time and in the Stephens Fall Investment Conference at The New York Palace in New York, New York on Wednesday, November 13, 2013 at 2:00 P.M. Eastern Time.
Marten Transport Announces Third Quarter Results
GlobeNewswire - Tue Oct 15, 3:02PM CDT
Marten Transport, Ltd. (Nasdaq:MRTN) today reported the highest net income for any quarter in the company's history. Net income improved 22.4% to $8.0 million, or 24 cents per diluted share, for the third quarter ended September 30, 2013, from $6.5 million, or 20 cents per diluted share, for the third quarter of 2012. For the nine-month period ended September 30, 2013, net income increased 16.9% to $22.8 million, or 68 cents per diluted share, from $19.5 million, or 59 cents per diluted share, for the 2012 nine-month period.
22.5% Return Seen to Date on SmarTrend Marten Transport Call (MRTN)
Comtex SmarTrend(R) - Fri Sep 20, 11:10AM CDT
SmarTrend identified an Uptrend for Marten Transport (NASDAQ:MRTN) on May 3rd, 2013 at $14.24. In approximately 5 months, Marten Transport has returned 22.54% as of today's recent price of $17.45.
Marten Transport Has Returned 19.9% Since SmarTrend Recommendation (MRTN)
Comtex SmarTrend(R) - Fri Sep 13, 9:50AM CDT
SmarTrend identified an Uptrend for Marten Transport (NASDAQ:MRTN) on May 3rd, 2013 at $14.24. In approximately 4 months, Marten Transport has returned 19.94% as of today's recent price of $17.08.
Marten Transport Has Returned 25.6% Since SmarTrend Recommendation (MRTN)
Comtex SmarTrend(R) - Thu Aug 29, 5:01PM CDT
SmarTrend identified an Uptrend for Marten Transport (NASDAQ:MRTN) on May 3rd, 2013 at $14.24. In approximately 4 months, Marten Transport has returned 25.56% as of today's recent price of $17.88.
Uptrend Call Working As Marten Transport Stock Rises 29.7% (MRTN)
Comtex SmarTrend(R) - Thu Aug 22, 11:03AM CDT
SmarTrend identified an Uptrend for Marten Transport (NASDAQ:MRTN) on May 3rd, 2013 at $14.24. In approximately 4 months, Marten Transport has returned 29.71% as of today's recent price of $18.47.
Marten Transport Shares Up 20.5% Since SmarTrend's Buy Recommendation (MRTN)
Comtex SmarTrend(R) - Wed Jul 31, 5:07PM CDT
SmarTrend identified an Uptrend for Marten Transport (NASDAQ:MRTN) on May 3rd, 2013 at $14.24. In approximately 3 months, Marten Transport has returned 20.51% as of today's recent price of $17.16.